Hematol Oncol. 2020 Jul 23. doi: 10.1002/hon.2781. Online ahead of print.
Current care for patients with follicular lymphoma (FL) offers most of them long-term survival. Improving it further will require careful patient selection. This review focuses on predictive biomarkers (i.e., those whose outcome correlations depend on the treatment strategy) in FL, because awareness of what patient subsets benefit most or least from each therapy will help in this task. The first part of this review aims to summarize what biomarkers are predictive in FL, the magnitude of the
effect and the quality of the evidence. We find predictive biomarkers in the setting of 1) indication of active treatment, 2) front-line induction (use of anthracyline-based regimens, CHOP vs. bendamustine, addition of rituximab) 3) post-(front-line)induction (rituximab maintenance, radioimmunotherapy) and 4) relapse (hematopoietic stem cell transplant) and targeted agents. The second part of this review discusses the challenges of precision medicine in FL, including 1) cost, 2) clinical relevance considerations and 3) difficulties over the broad implementation of biomarkers. We then provide our view on what biomarkers may become used in the next few years. We conclude by underscoring the importance of assessing the potential predictiveness of available biomarkers to improve patient care but also that there is a long road ahead before reaching their broad implementation due to remaining scientific, technological, and economic hurdles. This article is protected by copyright. All rights reserved.